CAJ | 학술논문

目的研究抵抗素在过氧化物酶增殖物激活受体(PPAR-γ)激动剂(罗格列酮)对大鼠重症急性胰腺炎(SAP)及其合并肺损伤防治中的作用及其作用机制.方法用ELISA法检测大鼠血清淀粉酶(AMY)、抵抗素、肿瘤坏死因子(TNF-α)、白细胞介素-1β(IL-1β)和C.反应蛋白(CRP)的水平变化,检测肺组织髓过氧化物酶(MPO)、肺湿/干重比值、胰腺/体质量比值、胰腺和肺组织病理变化；免疫组化检测胰腺组织中抵抗素的表达；实时定量PCR法检测胰腺组织中抵抗素mRNA的水平.结果罗格列酮预防组和治疗组大鼠血清AMY、抵抗素、TNF-α、IL-1B和CRP水平较SAP组均明显下降(均P＜0.01),预防组和治疗组与对照组相比均有明显升高(均P＜0.01),预防组和治疗组之间相比较有所变化,但两者之间无统计学意义；罗格列酮预防和治疗组胰腺/体质量比、胰腺病理评分、肺组织MPO含量和肺的病理评分较SAP组均明显降低(均P＜0.01)；对照组、SAP组、预防组和治疗组大鼠的胰腺组织抵抗素mRNA相对表达量(RQ值)较SAP组明显降低(均P＜0.01),而与对照组相比较均明显升高(P＜0.01),但预防组与治疗组之间差异无统计学意义.结论罗格列酮对SAP及合并肺损伤有明显的预防和治疗作用.
목적 연구저항소재과양화물매증식물격활수체(PPAR-γ)격동제(라격렬동)대대서중증급성이선염(SAP)급기합병폐손상방치중적작용급기작용궤제.방법 용ELISA법검측대서혈청정분매(AMY)、저항소、종류배사인자(TNF-α)、백세포개소-1β(IL-1β)화C.반응단백(CRP)적수평변화,검측폐조직수과양화물매(MPO)、폐습/간중비치、이선/체질량비치、이선화폐조직병리변화；면역조화검측이선조직중저항소적표체；실시정량PCR법검측이선조직중저항소mRNA적수평.결과 라격렬동예방조화치료조대서혈청AMY、저항소、TNF-α、IL-1B화CRP수평교SAP조균명현하강(균P＜0.01),예방조화치료조여대조조상비균유명현승고(균P＜0.01),예방조화치료조지간상비교유소변화,단량자지간무통계학의의；라격렬동예방화치료조이선/체질량비、이선병리평분、폐조직MPO함량화폐적병리평분교SAP조균명현강저(균P＜0.01)；대조조、SAP조、예방조화치료조대서적이선조직저항소mRNA상대표체량(RQ치)교SAP조명현강저(균P＜0.01),이여대조조상비교균명현승고(P＜0.01),단예방조여치료조지간차이무통계학의의.결론 라격렬동대SAP급합병폐손상유명현적예방화치료작용.
Objective To study the role and mechanism of resisitin in prophylactic and therapeutic treatments of rosiglitazone,a specific peroxisome proliferator-activated receptor-γ(PPARγ) ligand,in rats with severe acute pancreatitis (SAP) and pancreatitis-associated pulmonary injury.Methods The levels of amylase ( AMY ),Resistin,TNF-α,IL-1 β and C reactive protein (CRP) in blood plasma,lung myeloperoxidase ( MPO ) activity,pancreas/body weight ratio and lung wet/dry weight ratio were evaluated.Pancreatic and pulmonary pathology were observed.The expression of resistin in pancreas was detected byimmunohistochemistry.The gene expression of resistin mRNA was investigated by real-time PCR.Results Both prophylactic and therapeutic treatments with rosiglitazone could obviously ameliorate the levels of AMY,resistin,TNF-αt,IL-1β and CRP ( all P ＜ 0.01 ).Compared with the control group,both prophylactic and therapeutic treatment groups were higher( all P ＜ 0.01 ).The prophylactic treatment group was not different from the therapeutic treatment group.Both prophylactic and therapeutic treatments with rosiglitazone could significantly reduce pancreas/body weight ratio,pancreatic pathology,MPO,pulmonary pathology ( all P ＜ 0.01 ).Compared with the SAP group,the expression of resistin mRNA in the prophylactic and therapeutic treatment groups were obviously decreased.Conclusion Rosiglitazone could obviously ameliorate pancreatitis and pulmonary injury induced by L-arginine.